ABIOMED's Impella RP Bags CE Mark - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 5:50PM CDT
Shares of ABIOMED climbed 2.8% following the announcement last week, to close at $24.48 till the last closing date.
Is A Short Squeeze Ahead for Accuray (ARAY)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 9:47AM CDT
Is A Short Squeeze Ahead for Accuray (ARAY)?
Accuray Upped to Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 16, 1:50PM CDT
Accuray's year-over-year loss narrowed primarily due to robust top-line improvement of 20% from the year-ago period.
Health Care Sector Stocks under Review -- Research on Wright Medical, Globus Medical, Intuitive Surgical, and Accuray
PR Newswire - Tue Apr 15, 10:03AM CDT
The trading session on Monday, April 14, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,173.24, up 0.91% and the NASDAQ Composite closed at 4,022.69, up 0.57%. The S&P 500 finished the session 0.82% higher at 1,830.61. The gains were broad based as all the ten sectors finished on a positive note. The S&P 500 Health Care Sector Index finished the day at 648.05, up 0.51%, while the same has lost 1.86% in the last three months. Investor-Edge has initiated coverage on the following equities: Wright Medical Group Inc. (NASDAQ: WMGI), Globus Medical Inc. (NYSE: GMED), Intuitive Surgical Inc. (NASDAQ: ISRG) and Accuray Inc. (NASDAQ: ARAY). Free technical research on WMGI, GMED, ISRG and ARAY can be downloaded upon signing up at:
Will Obamacare Lead to a Medical Device Innovation Revolution?
Sean Williams, The Motley Fool - Motley Fool - Sun Apr 13, 11:31AM CDT
The first year of Obamacare enrollment is officially in the books, and more than 7 million people enrolled for health insurance on a state or federally run Obamacare exchange. This figure more or less matches projected enrollment targets from the...
Accuray to Report Financial Results for Third Quarter Fiscal 2014
GlobeNewswire - Thu Apr 10, 3:35PM CDT
Accuray Incorporated (Nasdaq:ARAY) announced today that it will report results for its third quarter of fiscal 2014, ended March 31, 2014 on Wednesday, April 30, 2014 after the market closes.
Financial Results Schedules, Approvals, Appointments, Product Launches, and Stock Movements - Analyst Notes on Allergan, Accuray, Cerus, Galena Biopharma, and ZELTIQ Aesthetic
PR Newswire - Wed Apr 09, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Allergan Inc. (NYSE: AGN), Accuray Incorporated (NASDAQ: ARAY), Cerus Corporation (NASDAQ: CERS), Galena Biopharma, Inc. (NASDAQ: GALE), and ZELTIQ Aesthetics, Inc. (NASDAQ: ZLTQ). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
The European CyberKnife Center Munich is celebrating its 5,000th patient treatment using the CyberKnife(R) System
PR Newswire Europe - Mon Apr 07, 7:31AM CDT
-- Where experience and state-of-the-art technology meet
The European CyberKnife Center Munich is celebrating its 5,000th patient treatment using the CyberKnife® System
CNW Group - Mon Apr 07, 7:30AM CDT
Where experience and state-of-the-art technology meet
Accuray Identifies EIMEA Region as Growth Territory
PR Newswire Europe - Thu Apr 03, 7:31AM CDT
- Acceptance of Accuray technologies in key markets adds to company's global market share
Accuray Up 26.4% Since SmarTrend Uptrend Call (ARAY)
Comtex SmarTrend(R) - Mon Mar 31, 5:00PM CDT
SmarTrend identified an Uptrend for Accuray (NASDAQ:ARAY) on November 8th, 2013 at $7.60. In approximately 5 months, Accuray has returned 26.40% as of today's recent price of $9.60.
Accuray Incorporated's CyberKnife(R) M6(TM) System Receives Shonin Approval
PR Newswire Europe - Thu Mar 27, 7:31AM CDT
-- Latest CyberKnife technology now available in Japan
Accuray Incorporated's CyberKnife® M6(TM) System Receives Shonin Approval
CNW Group - Thu Mar 27, 7:31AM CDT
Latest CyberKnife technology now available in Japan
Global Radiation Therapy Equipment Market 2014-2018: Key Regions, Key Vendors and Key Market Trends
M2 - Wed Mar 26, 5:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v2bjnr/global_radiation) has announced the addition of the "Global Radiation Therapy Equipment Market 2014-2018" report to their offering. Radiation therapy equipment is used to perform radiation therapy, also known as radiotherapy or radiation oncology, which is a procedure used in the treatment of cancer. It involves delivering high doses of radiation consisting of photons, electrons or gamma rays to kill cancer cells and reduce the rate at which the cancerous cells multiply by damaging the DNA inside the tumor cells. Radiation therapy is used to treat cancers of the head and neck, bladder, and lung as well as Hodgkin's disease. Radiation therapy can be administered in several ways. The type of therapy prescribed by oncologists depends on factors such as the type of cancer, the stage of the cancer, the size of the tumor, the position of the tumor in the body, the age of the patient, and the patient's medical history. Radiation therapy can either be given independently or in conjunction with other cancer treatments such as surgery and chemotherapy. The analysts forecast the Global Radiation Therapy Equipment market will grow at a CAGR of 6.04 percent over the period 2013-2018. Key Regions - Americas - EMEA - APAC Key Vendors - Accuray Inc. - Elekta AB - Siemens Healthcare - Varian Medical Systems Inc. Other Prominent Vendors - Best Theratronics Ltd. - Brainlab AG - C.R. Bard Inc. - Eckert & Ziegler BEBIG - GE Healthcare Ltd. - Hitachi America Ltd. - Ion Beam Applications SA - Philips Healthcare - RaySearch Laboratories AB Key Market Drivers - Increase in Aging Population. - For a full, detailed list, view our report. For more information visit http://www.researchandmarkets.com/research/v2..._radiation About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
20.5% Return Seen to Date on SmarTrend Accuray Call (ARAY)
Comtex SmarTrend(R) - Mon Mar 24, 11:06AM CDT
SmarTrend identified an Uptrend for Accuray (NASDAQ:ARAY) on November 8th, 2013 at $7.60. In approximately 5 months, Accuray has returned 20.47% as of today's recent price of $9.15.
Medical Robots Market by Type & Application - Global Forecasts to 2018 for the $1,781 Million Market
M2 - Fri Mar 21, 9:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mwj8xd/medical_robots) has announced the addition of the "Medical Robots Market by Type (Surgical Robot, Rehabilitation Robotics, Telemedicine, Assistive Robots, Orthotics, Prosthetics, Radio Surgery, Exoskeleton) & Application (Orthopedic, Neurology, Laparoscopy)- Global Forecasts to 2018" report to their offering. The medical robotics market was valued at $1,781 million in 2013 and is expected to reach $3,764 million by 2018, growing at a CAGR of 16.1% from 2013 to 2018 Over the years, the demand for medical robots has increased significantly. This is due to the paradigm shift in the healthcare industry where emphasis is being laid on minimally invasive surgeries through the use of robots. The global medical robot market is categorized into five broad segments - surgical robots, rehabilitation robots, non-invasive radiosurgery robots, hospital and pharmacy robots, and others. Based on applications, the medical robots market comprises the following segments - neurology, orthopedics, laparoscopy, special education, and other areas. . The hospital and pharmacy robots segment is the fastest-growing segment of the medical robotics market. The increasing demand for telemedicine robots is likely to propel the growth of this market. Along with this, technological developments and increasing adoption of newer technologies by hospitals are some factors that are propelling the demand for hospital and pharmacy robots. The other major segment under hospital and pharmacy robots is the i.v. robots segment. i.v. robots are dispensing robots used in hospitals and pharmacies to accurately compound drug mixtures. These robots are used to administer safe, accurate, efficient, cost-effective, and ready-to-administer IV admixtures. Factors such as an aging population, increasing spending power of the middle-class population, increasing number of private sector hospitals, advancements in endoscopic technologies, and expansions of rural healthcare facilities are also going to play a pivotal role in boosting the demand for medical robotics in the Asian region. China and Japan will be the focal point for the growth of medical robotics in the Asian market. Countries such as Singapore and Thailand are also expected to witness growth in this sector, owing to increasing government support. North America and Europe are both likely to witness an increasing demand for medical robotics owing to technological advancements as well as increased government support in both the geographies. Scope of the Report Segment - Surgical Robots -- Orthopedic Surgical Robots -- Neurological Surgical Systems -- Laparoscopy Robotic Systems -- Steerable Robotic Catheters - Rehabilitation Robots -- Assistive Robots -- Prosthetics -- Orthotics -- Therapeutic Robots -- Exoskeleton Robotic Systems - Non-Invasive Radio surgery Robots - Hospital and Pharmacy Robots -- Telemedicine Robots -- I.V. Robots -- Pharmacy Robots - Others Application - Neurology - Orthopedics - Laparoscopy - Special Education - Others Companies Mentioned - Accuray, Inc. - Hansen Medical, Inc. - Health Robotics S.R.L. - Intuitive Surgical Inc. - Mako Surgical Corp. - Mazor Robotics Ltd. - Medrobotics Corporation - Or Productivity Plc - Renishaw Plc - Titan Medical Inc. For more information visit http://www.researchandmarkets.com/research/mw...cal_robots
Accuray Honored for Delivering 'World-Class' Customer Service
PR Newswire - Tue Mar 18, 7:30AM CDT
Accuray Incorporated (Nasdaq: ARAY), announced today it has received the NorthFace ScoreBoard AwardSM from Omega Management Group Corp. in recognition of achieving excellence in customer service and support in 2013. This is the third year in a row Accuray has received this award. Since 2000, the award has been presented annually to companies who, as rated solely by their own customers, exceeded expectations in customer satisfaction during the prior calendar year. Omega is an expert in customer experience management (CEM) strategy, and helps companies boost revenue and profits by consistently exceeding customer expectations for service quality.